Hasil Pencarian - Sravanthi Cheeti

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib

    Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib oleh Christine Bowman, Michael Dolton, Fang Ma, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Nastya Kassir, Yuan Chen

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors

    Predicting overall survival from tumor dynamics metrics using parametric statistical and machine learning models: application to patients with RET-altered solid tumors oleh Erick Velasquez, Nastya Kassir, Sravanthi Cheeti, Denison Kuruvilla, Rucha Sane, Steve Dang, Dale Miles, James Lu

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

    Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics oleh Kit Wun Kathy Cheung, Yang Tang, Doreen Anders, Teresa Barata, Astrid Scalori, Priya Agarwal, Rucha Sane, Sravanthi Cheeti

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations

    Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations oleh Julia Suchomel, Priya Agarwal, Doreen Anders, Kevin Hughes, Yang Tang, Rucha Sane, Astrid Scalori, Sunil Sharma, Sravanthi Cheeti

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS

    A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS oleh Jonathan S. Katz, Jeffrey D. Rothstein, Merit E. Cudkowicz, Angela Genge, Björn Oskarsson, Avis B. Hains, Chen Chen, Joshua Galanter, Braydon L. Burgess, William Cho, Geoffrey A. Kerchner, Felix L. Yeh, Arundhati Sengupta Ghosh, Sravanthi Cheeti, Logan Brooks, Lee Honigberg, Jessica A. Couch, Michael E. Rothenberg, Flavia Brunstein, Khema R. Sharma, Leonard van denBerg, James D. Berry, Jonathan D. Glass

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: